COVID-19 and the nicotinic cholinergic system

Eur Respir J. 2020 Jul 16;56(1):2001589. doi: 10.1183/13993003.01589-2020. Print 2020 Jul.

Abstract

The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options. https://bit.ly/2zfUZ1S

Publication types

  • Letter
  • Comment

MeSH terms

  • Betacoronavirus
  • COVID-19
  • Cholinergic Agents
  • Coronavirus Infections*
  • Humans
  • Nicotine*
  • Pandemics*
  • Pneumonia, Viral*
  • Pulmonary Disease, Chronic Obstructive*
  • SARS-CoV-2
  • Smokers

Substances

  • Cholinergic Agents
  • Nicotine